Xilio Therapeutics, Inc. — Director's Dealing 2021

Oct 22, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Xilio Therapeutics, Inc. (XLO)
CIK: 0001840233
Period of Report: 2021-10-21

Reporting Person: RiverVest Venture Fund IV, L.P. (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock (832120)		Indirect
Series C Preferred Stock	$		Common Stock (359324)		Indirect

Footnotes

F1: Each share of Series B Preferred Stock and Series C Preferred Stock has no expiration date and are convertible at any time at the election of the holder without payment of further consideration. Each share of Series B Preferred Stock and Series C Preferred Stock will automatically convert into one share of Common Stock upon the closing of the Issuer's initial public offering.

F2: The shares held by RiverVest Venture Fund IV, L.P. ("RiverVest IV") are indirectly held by RiverVest Venture Partners IV, L.P. ("RiverVest Partners IV"), which is the general partner of RiverVest IV. RiverVest Venture Partners IV, LLC is the general partner of RiverVest Partners IV.

F3: The individual managers of RiverVest Ventures Partners IV, LLC are Jay Schmelter, John P. McKearn, Ph.D. and Niall O'Donnell. RiverVest Partners IV, RiverVest Venture Partners IV, LLC and each of the individual managers share voting and dispositive power with regard to the securities directly held by RiverVest Venture Fund IV, L.P.